Formycon

Formycon ROA

The Return on Assets (ROA) of Formycon (FYB.DE) as of Nov 20, 2026 is -8.75 %. In the previous year, Return on Assets (ROA) was -16.28 % — a change of -46.28% (higher).

ROA

-8.75 %

YoY

-46.28%

Last updated:

In 2025, Formycon's return on assets (ROA) was -8.75 %, a -46.28% increase from the -16.28 % ROA in the previous year.

The Formycon ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
17.92 EUR
Jan 1, 2019
-4.28 EUR
Jan 1, 2020
-8.90 EUR
Jan 1, 2021
-18.79 EUR
Jan 1, 2022
4.22 EUR
Jan 1, 2023
8.51 EUR
Jan 1, 2024
-16.28 EUR
Jan 1, 2025
-8.75 EUR
The Formycon ROA history
YEARROAYoY
-8.75 %-46.28%
-16.28 %-291.30%
8.51 %+101.92%
4.22 %-122.43%
-18.79 %+111.14%
-8.90 %+107.87%
-4.28 %-123.90%
17.92 %-449.24%
-5.13 %-68.23%
-16.14 %-858.89%
2.13 %-58.20%
5.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

ROA Details

Understanding Formycon's Return on Assets (ROA)

Formycon's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Formycon's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Formycon's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Formycon’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Formycon stock

Return on Assets (ROA) of Formycon is -8.75 % in 2025.

Return on Assets (ROA) of Formycon changed from -16.28 % to -8.75 %, representing a -46.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Formycon since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Formycon with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Formycon

All Key Metrics — Formycon